**Name of Journal: *World Journal of Gastrointestinal Oncology***

**ESPS Manuscript NO: 18541**

**Manuscript Type: TOPIC HIGHLIGHT**

**2015 Advances in Colorectal Cancer**

**Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer**

Kocoglu H *et al.* Clinical efficacy and drug resistance of anti-EGFR therapy in CRC

**Hakan Kocoglu, Fatih Mehmet Velibeyoglu, Mustafa Karaca, Deniz Tural**

**Hakan Kocoglu, Fatih Mehmet Velibeyoglu, Deniz Tural,** Department of Medical Oncology, Bakirkoy Education and Research Hospital, 34900 Istanbul, Turkey

**Mustafa Karaca,** Department of Medical Oncology, Gazi University Faculty of Medicine, 06500 Ankara, Turkey

**Author contributions:** All authors contributed to this manuscript.

**Conflict-of-interest** **statement:** All authors declared no conflict of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to: Deniz Tural, MD,** Department of Medical Oncology, Bakirkoy Education and Research Hospital, Zuhuratbaba District, Tevfik Saglam Street, No: 11, 34900 Istanbul, Turkey. deniztural@gmail.com

**Telephone: +90-212-4147171**

**Fax: +90-212-4147172**

**Received:** April 23, 2015

**Peer-review started:** April 24, 2015

**First decision:** September 2, 2015

**Revised:** November 12, 2015

**Accepted:** December 7, 2015

**Article in press:**

**Published online:**

**Abstract**

Colorectal cancer (CRC) ranked third in cancer related death and its incidence has been increasing worldwide. In recent decades important therapeutic advances have been developed in treatment of metastatic CRC (mCRC), such as monoclonal antibodies against epidermal growth factor receptor (anti-EGFR), which provided additional clinical benefits in mCRC. However, anti-EGFR therapies have limited usage due to approximately 95% of patients with KRAS mutated mCRC do not response to anti-EGFR treatment. Thus, KRAS mutation is predictive of nonresponse to anti-EGFR therapies but it alone is not a sufficient basis to decide who should not be received such therapies because; approximately fifty percent (40%-60%) of CRC patients with wild-type KRAS mutation also have poor response to anti-EGFR based treatment. This fact leads us to suspect that there must be other molecular determinants of response to anti-EGFR therapies which have not been identified yet. Current article summarizes the clinical efficacy of anti-EGFR therapies and also evaluates its resistance mechanisms.

**Key words:** Colorectal cancer; Epidermal growth factor receptor; KRAS mutation; Drug resistance; Anti-epidermal growth factor receptor antibody

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Molecular targeting agents, such as monoclonal antibodies against epidermal growth factor receptor (anti-EGFR), provide additional clinical benefits in metastatic colorectal cancer. However, anti-EGFR therapies have limited usage due to approximately 95% of patients with KRAS mutated metastatic colorectal cancer (mCRC) do not response to anti-EGFR treatment. Thus, KRAS mutation is predictive of nonresponse to anti-EGFR therapies but it alone is not a sufficient basis to decide who should not be received such therapies because approximately fifty percent (40%-60%) of CRC patients with wild-type KRAS mutation also have poor response to anti-EGFR based treatment. This fact leads us to suspect that there must be other molecular determinants of response to anti-EGFR therapies which have not been identified yet. Current article summarizes the clinical efficacy of anti-EGFR therapies and also evaluates its resistance mechanisms.

Kocoglu H, Velibeyoglu FM, Karaca M, Tural D. Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer. *World J Gastrointest Oncol* 2015; In press

**INTRODUCTION**

Colorectal cancer (CRC) is one of the most commonly diagnosed cancers in both genders (second in females and third in males)[1]; and it is also ranked third in cancer related death in both genders with approximately 15.1 deaths per 100000[2,3]. While the mortality rate of CRC has been decreasing in Western countries, its incidence has been increasing worldwide, except United States[4]. Despite of decreasing death rates, approximately fifty percent of patients with CRC are diagnosed with metastatic disease in their initial assessments[5].

Several chemotherapeutic agents [*e.g*., [pyrimidine analog](https://en.wikipedia.org/wiki/Pyrimidine_analog)s (*e.g.*, 5-fluorouracil), platinum-based antineoplastic agents, and topoisomerase inhibitors] have become available in the past and thus survival rate of CRC patients significantly increased. Also, recently developed molecular targeting agents, such as monoclonal antibodies against epidermal growth factor receptor (EGFR) (*e.g.*, cetuximab and panitumumab)[6,7], provided additional clinical benefits in metastatic CRC (mCRC)[8-10].

In several types of cancer, including CRC, EGFR is overexpressed or amplified. Monoclonal antibodies keep EGFR in an inactive state by binding to and occluding the ligand-binding site of EGFR when the ligand is unbound (acting as competitive antagonists). This leads an inhibition of intracellular signaling pathways of EGFR (RAS/RAF/MAPK and PI3K/PTEN/AKT) that involved in several cellular activities including cell proliferation, motility, invasion, and survival[11].

KRAS, a signal transduction molecule, transduces the signal from ligand-bound EGFR to the nucleus. Prospective randomized trials elucidated that presence of mutation in *KRAS* gene leads to non-response to anti-EGFR based treatment[6-10,12-14]. Therefore, it is highly recommended that KRAS mutation status should be known before initiating anti-EGFR based treatment in mCRC patients. Thus, KRAS mutation is predictive of nonresponse to anti-EGFR therapies but it alone is not a sufficient basis to decide who should not be received such therapies because almost 60% of CRC patients with wild-type KRAS mutation also have poor response to anti-EGFR based treatment[15]. This fact leads us to suspect that there must be other molecular determinants of response to anti-EGFR therapies which have not been identified yet. Current article summarizes the clinical efficacy of anti-EGFR therapies and also evaluates its resistance mechanisms.

**CLINICAL EFFICACY OF ANTI-EGFR ANTIBODY IN METASTATIC CRC**

Both Cetuximab, an IgG1 type chimeric monoclonal antibody, and panitumumab, an IgG2 type fully human monoclonal antibody, induce apoptosis by inhibiting downstream signaling pathways of EGFR (RAS/RAF/MAPK and PI3K/PTEN/AKT). Also, these molecules, especially cetuximab, activate antibody-dependent cellular cytotoxicity which consequently improves their cytotoxic actions and therapeutic effectiveness[16].

The recent published randomized non-inferiority phase III study showed median overall survival (OS) was similar in patients with mCRC who treated with panitumumab alone and with cetuximab alone[17]. The incidences of any grade and grade 3-4 adverse events were similar in both treatment groups, however, the incidence of grade 3-4 infusion reaction was lower and grade 3-4 hypomagnesaemia was higher in panitumumab group than in cetuximab group[18]. In some studies, cetuximab and panitumumab have been investigated in combination with FOLFIRI (folinic acid, fluorouracil, and irinotecan) and FOLFOX (folinic acid, fluorouracil, and oxaliplatin) as initial therapy option for treatment of mCRC. And a meta-analysis of these 14 randomized studies concluded that there is a clear benefit to the use EGFR inhibitors in patients with wild-type (WT) KRAS mCRC[18]. An updated analysis (CRYSTAL trial) demonstrated that adding cetuximab to FOLFIRI as first-line therapy improves survival in patients with WT KRAS mCRC[19]. Also another randomized phase III study showed that the combination of panitumumab and FOLFIRI significantly improves progression-free survival (PFS), but not OS, in mCRC patients with WT KRAS[9]. Three other trials have evaluated the addition of cetuximab to FOLFOX in first line treatment of patients WT KRAS mCRC. In randomized phase II OPUS study, combination of FOLFOX and cetuximab was associated with increased response rate and PFS. However, this treatment had no benefit in median OS[12]. In the Medical Research Council (MRC) COIN study, adding cetuximab to oxaliplatin-based chemotherapy in patients with WT KRAS mCRC increased response rate with no benefit in PFS or OS[20]. Similarly, another phase III study (NORDIC-VII) showed that cetuximab did not add significant benefit when combined with FOLFOX in treatment of patients with WT KRAS mCRC[21]. In contrast to earlier studies, the recent published randomized phase III CALGB/SWOG 80405 trial demonstrated that addition of cetuximab to FOLFOX or FOLFIRI chemotherapy was significantly increased PFS and OS in treatment of patients with all RAS-WT mCRC[22]. In the study by Douillard *et al*[23] (the PRIME study), which compared panitumumab plus FOLFOX and FOLFOX alone in mCRC patients with WT KRAS/NRAS, panitumumab plus FOLFOX group showed a statistically significant improvement in PFS and OS.

Based on this knowledge, all patients with newly diagnosed mCRC should be tested for KRAS mutation. Also screening of KRAS mutations seems essential in mCRC patients to initiate anti-EGFR based treatment. But KRAS mutation alone is not a sufficient basis to decide who should not be received such therapies because almost 60% of CRC patients with WT KRAS mutation also have poor response to anti-EGFR based treatment[15]. Also 5%-9% of CRC patients have a specific mutation in *BRAF* gene (V600E)[24,25]. But the use of BRAF as a predictive marker for response to anti-EGFR based treatment is unclear. This fact leads us to suspect that there must be other molecular determinants of response to anti-EGFR therapies which have not been identified yet.

**MECHANISMS OF RESISTANCE TO ANTI-EGFR TREATMENT**

***KRAS/NRAS/BRAF mutations***

Approximately 40% of CRC patients have mutation in exon 2 of the coding of the *KRAS* gene[26,27]. Prospective randomized studies showed that KRAS mutations are predictive of non-response to anti-EGFR based treatment[6-10,12-14]. These studies showed that tumors with a mutation in codon 12 or 13 of exon 2 of the KRAS gen are essentially unresponsive to anti-EGFR based treatment. Recent studies demonstrated that mutation in KRAS outside of exon 2 and mutation in NRAS are also predictive for unresponsiveness to ant-EGFR treatment[23,28]. Recently, a study assessed the superiority of FOLFOX plus panitumumab to FOLFOX alone according to RAS (KRAS or NRAS) or BRAF (B-type Raf kinase) mutation status. In that study, 17% of patients with non-mutated KRAS exon 2 had other RAS mutation which has been shown to be associated with inferior survival with panitumumab plus FOLFOX treatment[23]. Cetuximab or panitumumab treatments seem to be eligible for selected patients with WT KRAS tumors who also have BRAF-WT mutations[29].

BRAF oncogene encodes BRAF protein which is a member of RAS/RAF/MAPK (mitogen-activated protein kinase) pathway[27]. Mutations in *BRAF* and *KRAS* genes are mutually exclusive[30]. Approximately 9% (5%-9%) of patients with CRC have a mutation in *BRAF* gene (V600E)[24,25]. CRYSTAL and PETACC-3 studies demonstrated that patients with BRAF mutation have a worse prognosis than those with the WT tumors[19,31]. However, the use of BRAF as a predictive marker is unclear. CRYSTAL study elucidated that BRAF mutation does not seem to be strong predictive biomarker for the addition cetuximab to FOLFIRI in the first line treatment of WT mCRC[19]. Also, subset analysis of the PRIME study found that BRAF mutation indicates poor prognosis but it may not be predictive of the benefit of adding panitumumab to FOLFOX in the first line treatment of mCRC[8]. Tol *et al*[25] demonstrated that *BRAF* mutation is a negative indicator for prognosis in mCRC patients and in contrast to KRAS mutation, this feature is not restricted to the outcome of the cetuximab. In subsequent lines of therapy elucidated that BRAF mutation is a marker of resistance to anti-EGFR treatment in the non-first line setting of mCRC[29,32,33].

Vemurafenib is orally administered selective inhibitor of BRAF V600 kinase but using it alone in BRAF–mutated CRC patients results insufficient activity[34]. Studies suggested that feedback activation of EGFR signaling might be responsible of the resistance to Vemurafenib in CRC[35,36]. In a cohort study by Hyman *et al*[37], median PFS and OS did not change with vemurafenib monotherapy or vemurafenib and cetuximab combination therapy in patients with CRC (Table 1).

**HYPERACTIVATION OF PI3K-PTEN AXIS**

Interestingly, 41% of patients do not have KRAS or BRAF mutation, and they do not respond to anti-EGFR treatment[29]. Some studies suggested that anti-EGFR downstream pathways other than RAS/RAF/MAPK [*e.g*., phosphoinositide 3-kinase/phosphatase and tensin homolog pathway (PI3K/PTEN)], might be responsible for the resistance to anti-EGFR based therapy. It was shown that mutation in PI3KCA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) or loss of PTEN is associated with resistance to anti-EGFR based treatment[38-40]. Tural *et al*[41] investigated the effect of oncogenic activation of the members of EGFR downstream pathways (*e.g.*, PI3K, PTEN and BRAF) on response to anti-EGFR therapy. They have showed that PI3K expression and PTEN loss might be used as predictive to the response to anti-EGFR treatment in mCRC patients with WT KRAS. According to this study, BRAF negative, PTEN expressing and PI3K non-expressing CRCs have higher response rate and longer PFS and OS than all others. Most studies evaluated PI3K mutation in response to cetuximab based treatments in CRC patients[38,42-45]. In these studies, PI3K mutation has been suggested as predictive of resistance to anti-EGFR-based therapies. On the other hand, the role of PI3K mutation in response is conflict. Perrone *et al*[38] has investigated *PI3KCA* gene mutations in CRC patients and they suggested that mutation in PI3KCA causes resistance to anti-EGFR therapies. Also Prenen *et al*[45] analyzed PI3CA and KRAS mutations status in chemo-refractory mCRC patients who treated with anti-EGFR based treatment and they did not determine any correlation between PI3KCA mutation and response to anti-EGFR treatment. Nevertheless, most of studies have suggested that PTEN inactivation is a negative predictor of response to anti-EGFR therapy[38-40]. Bardellie *et al*[46] stated that PI3K expression and PTEN loss are correlated with decreased survival and are predictors of poor response to anti-EGFR therapy. Based on these studies, it is well known that activating mutation in PI3KCA or inactivation of PTEN phosphates can deregulate PI3K signaling pathway[46]. Two studies demonstrated that PI3KCA mutation and PTEN loss which cause PI3K pathway activation are significant predictors of response to anti-EGFR treatment[38,42]. Also, Tural *et al*[41] indicated that PI3K expression and PTEN loss together are correlated with significantly worse outcome.

**HYPEREXPRESSION OR HYPERACTIVATION OF TYPE 1 INSULIN LIKE GROWTH FACTOR RECEPTOR**

The type 1 insulin like growth factor receptor (IGF-1R) belongs to the class of tyrosine kinase receptors. IGF-1R functions by activating downstream signaling pathways which include MAPK and PI3K/AKT. Previous studies showed that IGF-1R overexpression results neoplastic transformation of cultured cells[47]. Also IGF-1R overexpression was seen in several types of human tumors[48] and its downregulation has been shown to be able to inhibit the growth of these cells[49]. These findings make IGF-1R an attractive candidate as therapeutic target in anti-tumor therapies. A previous study showed that combination therapy of antibodies against to IGF-1R and anti-EGFR results in further inhibition of CRC cell line growth[50]. A phase II study evaluated the safety and the efficacy of human anti-IGF-1R monoclonal antibody (either alone or in combination with cetuximab) in mCRC patients, and both treatment modalities was reported as insufficient in chemorefractory mCRC patients[51] (Table 1).

**REFERENCES**

1 **Jemal A**, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* 2011; **61**: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]

2 **Jemal A**, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. *CA Cancer J Clin* 2009; **59**: 225-249 [PMID: 19474385 DOI: 10.3322/caac.20006]

3 **Alberts SR**, Wagman LD. Chemotherapy for colorectal cancer liver metastases. *Oncologist* 2008; **13**: 1063-1073 [PMID: 18838438 DOI: 10.1634/theoncologist.2008-0142]

4 **Siegel RL**, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin* 2015; **65**: 5-29 [PMID: 25559415 DOI: 10.3322/caac.21254]

5 **Centers for Disease Control and Prevention**. United States Cancer Statistics: US Cancer Statistics Working Group, 2013. Available from: URL: http://www.cdc.gov/uscs

6 **Van Cutsem E**, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med* 2009; **360**: 1408-1417 [PMID: 19339720 DOI: 10.1056/NEJMoa0805019]

7 **Cunningham D**, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N Engl J Med* 2004; **351**: 337-345 [PMID: 15269313 DOI: 10.1056/NEJMoa033025]

8 **Douillard JY**, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. *J Clin Oncol* 2010; **28**: 4697-4705 [PMID: 20921465 DOI: 10.1200/JCO.2009.27.4860]

9 **Peeters M**, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. *J Clin Oncol* 2010; **28**: 4706-4713 [PMID: 20921462 DOI: 10.1200/JCO.2009.27.6055]

10 **Van Cutsem E**, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. *J Clin Oncol* 2007; **25**: 1658-1664 [PMID: 17470858 DOI: 10.1200/JCO.2006.08.1620]

11 **Ciardiello F**, Tortora G. EGFR antagonists in cancer treatment. *N Engl J Med* 2008; **358**: 1160-1174 [PMID: 18337605 DOI: 10.1056/NEJMra0707704]

12 **Bokemeyer C**, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. *J Clin Oncol* 2009; **27**: 663-671 [PMID: 19114683 DOI: 10.1200/JCO.2008.20.8397]

13 **Karapetis CS**, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. *N Engl J Med* 2008; **359**: 1757-1765 [PMID: 18946061 DOI: 10.1056/NEJMoa0804385]

14 **Heinemann V**, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. *Lancet Oncol* 2014; **15**: 1065-1075 [PMID: 25088940 DOI: 10.1016/S1470-2045(14)70330-4]

15 **Linardou H**, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA, Murray S. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. *Lancet Oncol* 2008; **9**: 962-972 [PMID: 18804418 DOI: 10.1016/S1470-2045(08)70206-7]

16 **Scott AM**, Wolchok JD, Old LJ. Antibody therapy of cancer. *Nat Rev Cancer* 2012; **12**: 278-287 [PMID: 22437872 DOI: 10.1038/nrc3236]

17 **Price TJ**, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Zhang K, Murugappan S, Sidhu R. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. *Lancet Oncol* 2014; **15**: 569-579 [PMID: 24739896 DOI: 10.1016/S1470-2045(14)70118-4]

18 **Vale CL**, Tierney JF, Fisher D, Adams RA, Kaplan R, Maughan TS, Parmar MK, Meade AM. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. *Cancer Treat Rev* 2012; **38**: 618-625 [PMID: 22118887 DOI: 10.1016/j.ctrv.2011.11.002]

19 **Van Cutsem E**, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. *J Clin Oncol* 2011; **29**: 2011-2019 [PMID: 21502544 DOI: 10.1200/JCO.2010.33.5091]

20 **Maughan TS**, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. *Lancet* 2011; **377**: 2103-2114 [PMID: 21641636 DOI: 10.1016/S0140-6736(11)60613-2]

21 **Tveit KM**, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. *J Clin Oncol* 2012; **30**: 1755-1762 [PMID: 22473155 DOI: 10.1200/JCO.2011.38.0915]

22 **Venook AP**, Niedzwiecki D, Lenz H-J, Innocenti F, Mahoney MR, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Mayer RJ, Schilsky RL, Bertagnolli MM, Blanke CD, (Alliance) CaLGB. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). *J Clin Oncol* 2014; **32**: 5s, 2014 (suppl; abstr LBA3)

23 **Douillard JY**, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. *N Engl J Med* 2013; **369**: 1023-1034 [PMID: 24024839 DOI: 10.1056/NEJMoa1305275]

24 **Cutsem EV**, Folprecht IL, Nowacki M, Barone C, Shchepotin I, Maurel J, Cunningham D, Celik I, Kohne C. Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome. *J Clin Oncol* 2010; **28** (May 20 Supply): 3570

25 **Tol J**, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. *N Engl J Med* 2009; **361**: 98-99 [PMID: 19571295 DOI: 10.1056/NEJMc0904160]

26 **Amado RG**, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J Clin Oncol* 2008; **26**: 1626-1634 [PMID: 18316791 DOI: 10.1200/JCO.2007.14.7116]

27 **Wan PT**, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. *Cell* 2004; **116**: 855-867 [PMID: 15035987]

28 **Sorich MJ**, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. *Ann Oncol* 2015; **26**: 13-21 [PMID: 25115304 DOI: 10.1093/annonc/mdu378]

29 **Di Nicolantonio F**, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. *J Clin Oncol* 2008; **26**: 5705-5712 [PMID: 19001320 DOI: 10.1200/JCO.2008.18.0786]

30 **Benvenuti S**, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. *Cancer Res* 2007; **67**: 2643-2648 [PMID: 17363584 DOI: 10.1158/0008-5472.CAN-06-4158]

31 **Roth AD**, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. *J Clin Oncol* 2010; **28**: 466-474 [PMID: 20008640 DOI: 10.1200/JCO.2009.23.3452]

32 **Laurent-Puig P**, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. *J Clin Oncol* 2009; **27**: 5924-5930 [PMID: 19884556 DOI: 10.1200/JCO.2008.21.6796]

33 **Loupakis F**, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. *Br J Cancer* 2009; **101**: 715-721 [PMID: 19603018 DOI: 10.1038/sj.bjc.6605177]

34 **Kopetz S**, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Lee RJ, Nolop KB, Saltz L. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. *J Clin Oncol* 2010; **28** Suppl: 15s. abstract

35 **Prahallad A**, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. *Nature* 2012; **483**: 100-103 [PMID: 22281684 DOI: 10.1038/nature10868]

36 **Corcoran RB**, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M, Engelman JA. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. *Cancer Discov* 2012; **2**: 227-235 [PMID: 22448344 DOI: 10.1158/2159-8290.CD-11-0341]

37 **Hyman DM**, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzen F, Veronese ML, Tabernero J, Baselga J. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. *N Engl J Med* 2015; **373**: 726-736 [PMID: 26287849 DOI: 10.1056/NEJMoa1502309]

38 **Perrone F**, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, Frattini M, Riva C, Andreola S, Bajetta E, Bertario L, Leo E, Pierotti MA, Pilotti S. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. *Ann Oncol* 2009; **20**: 84-90 [PMID: 18669866 DOI: 10.1093/annonc/mdn541]

39 **Frattini M**, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. *Br J Cancer* 2007; **97**: 1139-1145 [PMID: 17940504 DOI: 10.1038/sj.bjc.6604009]

40 **Loupakis F**, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I, Cascinu S, Falcone A. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. *J Clin Oncol* 2009; **27**: 2622-2629 [PMID: 19398573 DOI: 10.1200/JCO.2008.20.2796]

41 **Tural D**, Batur S, Erdamar S, Akar E, Kepil N, Mandel NM, Serdengeçti S. Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS. *Tumour Biol* 2014; **35**: 1041-1049 [PMID: 23996432 DOI: 10.1007/s13277-013-1138-8]

42 **Saridaki Z**, Tzardi M, Papadaki C, Sfakianaki M, Pega F, Kalikaki A, Tsakalaki E, Trypaki M, Messaritakis I, Stathopoulos E, Mavroudis D, Georgoulias V, Souglakos J. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients. *PLoS One* 2011; **6**: e15980 [PMID: 21283802 DOI: 10.1371/journal.pone.0015980]

43 **Mao C**, Yang ZY, Hu XF, Chen Q, Tang JL. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. *Ann Oncol* 2012; **23**: 1518-1525 [PMID: 22039088 DOI: 10.1093/annonc/mdr464]

44 **De Roock W**, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. *Lancet Oncol* 2010; **11**: 753-762 [PMID: 20619739 DOI: 10.1016/S1470-2045(10)70130-3]

45 **Prenen H**, De Schutter J, Jacobs B, De Roock W, Biesmans B, Claes B, Lambrechts D, Van Cutsem E, Tejpar S. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. *Clin Cancer Res* 2009; **15**: 3184-3188 [PMID: 19366826 DOI: 10.1158/1078-0432.CCR-08-2961]

46 **Bardelli A**, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. *J Clin Oncol* 2010; **28**: 1254-1261 [PMID: 20100961 DOI: 10.1200/JCO.2009.24.6116]

47 **Kaleko M**, Rutter WJ, Miller AD. Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation. *Mol Cell Biol* 1990; **10**: 464-473 [PMID: 2153917]

48 **Ouban A**, Muraca P, Yeatman T, Coppola D. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. *Hum Pathol* 2003; **34**: 803-808 [PMID: 14506643]

49 **Hailey J**, Maxwell E, Koukouras K, Bishop WR, Pachter JA, Wang Y. Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells. *Mol Cancer Ther* 2002; **1**: 1349-1353 [PMID: 12516969]

50 **Reinmuth N**, Liu W, Fan F, Jung YD, Ahmad SA, Stoeltzing O, Bucana CD, Radinsky R, Ellis LM. Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. *Clin Cancer Res* 2002; **8**: 3259-3269 [PMID: 12374697]

51 **Reidy DL**, Vakiani E, Fakih MG, Saif MW, Hecht JR, Goodman-Davis N, Hollywood E, Shia J, Schwartz J, Chandrawansa K, Dontabhaktuni A, Youssoufian H, Solit DB, Saltz LB. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. *J Clin Oncol* 2010; **28**: 4240-4246 [PMID: 20713879 DOI: 10.1200/JCO.2010.30.4154]

**P-Reviewer:**  Chae SC, Furka A, Li YY, Suarez J **S-Editor:** Ji FF **L-Editor: E-Editor:**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 1 Clinical trials of targeted agents in combination with chemotherapy as first-line treatments for metastatic colorectal cancer** | | | | | | | | | | |
| **Ref.** | **Year** | **Population** | **Patient number** | **Regimen** | **Median PFS (mo)** | ***P*1** | **Median OS (mo)** | ***P*1** | **Response rate (%)** | ***P*1** |
| CRYSTAL[19] | 2009 | All | 599 | FOLFIRI | 8 | **0.048** | 18.6 | 0.31 | 38.7 | **0.0038** |
| 599 | FOLFIRI + Cetuximab | 8.9 | 19.9 | 46.9 |
| KRAS WT subgroup | 350 | FOLFIRI | 8.4 | **0.0012** | 20 | **0.0093** | 39.7 | **< 0.001** |
| 316 | FOLFIRI + Cetuximab | 9.9 | 23.5 | 57.3 |
| KRAS MT subgroup | 183 | FOLFIRI | 7.7 | 0.26 | 16.7 | 0.75 | 36.1 | 0.35 |
| 214 | FOLFIRI + Cetuximab | 7.4 | 16.2 | 31.3 |
| OPUS[12] | 2009 | All | 168 | FOLFOX4 | 7.2 | 0.62 | 18 | 0.91 | 36 | 0.064 |
| 169 | FOLFOX4 + Cetuximab | 7.2 | 18.3 | 46 |
| KRAS WT subgroup | 97 | FOLFOX4 | 7.2 | **0.0064** | 18.5 | 0.39 | 34 | **0.0027** |
| 82 | FOLFOX4 + Cetuximab | 8.3 | 22.8 | 57 |
| KRAS MT subgroup | 59 | FOLFOX4 | 8.6 | 0.0153 | 17.5 | 0.2 | 53 | 0.029 |
| 77 | FOLFOX4 + Cetuximab | 5.5 | 13.4 | 34 |
| COIN[20] | 2011 | KRAS WT group | 367 | FOLFOX/XELOX | 8.6 | 0.60 | 17.9 | 0.68 | 57 | 0.049 |
| 362 | FOLFOX/XELOX + Cetuximab | 8.6 | 17 | 64 |
| KRAS WT group | 127 | FOLFOX | 9.2 | 0.056 | - | - | - | - |
| 117 | FOLFOX + Cetuximab | 9.0 | - | - |
| KRAS WT group | 240 | XELOX | 8.0 | 0.56 | - | - | - | - |
| 245 | XELOX + Cetuximab | 8.4 | - | - |
| KRAS MT group | 268 | FOLFOX/XELOX | - | - | 14.8 | 0.80 | - | - |
| 297 | FOLFOX/XELOX + Cetuximab | - | 13.6 | - |
| NORDIC-VII[21] | 2012 | All | 185 | Nordic FLOX (control group) | 7.9 | - | 20.4 | - | 41 | - |
| 194 | FLOX + Cetuximab | 8.3 | 0.31 | 19.7 | 0.67 | 49 | 0.15 |
| 187 | intermittent FLOX + Cetuximab | 7.3 | NA | 20.3 | 0.79 | 47 | NA |
| KRAS WT subgroup | 97 | Nordic FLOX (control group) | 8.7 | - | 22 | - | 47 | - |
| 97 | FLOX + Cetuximab | 7.9 | 0.66 | 20.1 | 0.48 | 46 | 0.89 |
| 109 | intermittent FLOX + Cetuximab | 7.5 | NA | 21.4 | 0.66 | 51 | NA |
| KRAS MT subgroup | 58 | Nordic FLOX (control group) | 7.8 | - | 20.4 | - | 40 | - |
| 72 | FLOX + Cetuximab | 9.2 | **0.07** | 21.1 | 0.89 | 49 | 0.31 |
| 65 | intermittent FLOX + Cetuximab | 7.2 | NA | 20.5 | 0.84 | 42 | NA |
| CALGB/SWOG[22] 80405 (study is ongoing) | 2014 | KRAS WT group | 578 | FOLFIRI or mFOLFOX6 + Cetuximab | 10.45 | NA | 29.93 | 0.34 | - | - |
| 559 | FOLFIRI or mFOLFOX6 + Bevacizumab | 10.84 | 29.04 | - |
| PRIME[8] | 2010 | KRAS WT group | 331 | FOLFOX4 | 8.0 | **0.02** | 19.7 | 0.072 | 48 | 0.068 |
| 325 | FOLFOX4 + Panitumumab | 9.6 | 23.9 | 55 |
| KRAS MT group | 219 | FOLFOX4 | 8.8 | **0.02** | 19.3 | 0.068 | 40 | - |
| 221 | FOLFOX4 + Panitumumab | 7.3 | 15.5 | 40 |
| Hyman *et al*[37] | 2015 | BRAF V600 group | 10 | Vemurafenib | 4.5 | - | 9.3 | - | 0 | - |
| 27 | Vemurafenib + Cetuximab | 3.7 | 7.1 | 4 |
| Reidy *et al*[48] | 2010 | All | 23 | IMC-A12 (anti-IGF-1R antibody) | 5.9 | - | 5.2 | - | 0 | - |
| 21 | IMC-A12 (anti-IGF-1R antibody) + Cetuximab | 6.1 | 4.5 | 5 |
| KRAS WT group | 20 | IMC-A12 (anti-IGF-1R antibody) + Cetuximab | 9.4 | 10.9 | 0 |
| 195% confidence interval. PFS: Progression-free survival; OS: Overall survival; All: All patients group; WT: Wild type; MT: Mutant type; NA: Not available; KRAS: KRAS exon 2, codons 12 and 13; FOLFIRI: Irinotecan, fluorouracil, and leucovorin; FOLFOX: Fluorouracil, leucovorin, and oxaliplatin; XELOX: Capecitabine and oxaliplatin; FLOX: Fluorouracil, leucovorin, and oxaliplatin. | | | | | | | | | | |